JUNE 7, 2024
Combined General Meeting of June 24, 2024 Biophytis will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université –
MAY 14, 2024
Biophytis announces the design of its phase 2 OBA clinical study in obesity Biophytis announces the design of its phase 2 OBA clinical study in
APRIL 29, 2024
Biophytis is deploying its partnership strategy in obesity Biophytis today the implementation of a dedicated strategy for partner search in obesity. Biophytis is continually working
APRIL 24, 2024
Biophytis Announces Transfer of ADSs to OTC Market ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company
APRIL 19, 2024
Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Biophytis annouces that it will change the ratio of its American Depositary Shares (the
APRIL 18, 2024
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming
APRIL 15, 2024
Biophytis files a patent application and strengthens its intellectual property in obesity Biophytis announces the filing of a patent application in the treatment of obesity,
APRIL 8, 2024
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study
APRIL 8, 2024
Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis publishes its financial results for the year ended December 31,
APRIL 4, 2024
RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 resolutions presented by the Company have been adopted Biophytis announces the approval of all the